

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EVEREST MEDICINES**

**云 頂 新 耀**

**Everest Medicines Limited**

**雲 頂 新 耀 有 限 公 司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1952)**

**VOLUNTARY ANNOUNCEMENT  
BUSINESS UPDATE ON THE SUBMISSION OF  
NEW DRUG APPLICATION IN HONG KONG FOR  
XERAVA™ FOR THE TREATMENT OF  
COMPLICATED INTRA-ABDOMINAL INFECTIONS**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the “**Board**”) is pleased to announce that submission of a New Drug Application (NDA) to the Department of Health, the Hong Kong Special Administrative Region, China, for Xerava™ (eravacycline) for the treatment of complicated intra-abdominal infections (“**cIAI**”) in adult patients in Hong Kong.

Xerava™ is currently approved for the treatment of cIAI in the United States (“**US**”), Europe (“**EU**”), United Kingdom (“**UK**”) and Singapore, and is currently under regulatory review for the treatment of cIAI in China.

In September 2020, Xerava™ was included in the Infectious Disease Society of America’s (IDSA) updated clinical guidelines on the treatment of antimicrobial resistant gram-negative infections and in March 2021, it was included in an expert consensus on the multidisciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, Infectious Diseases Society for Evidence-based and Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery.

## INFORMATION ABOUT COMPLICATED INTRA-ABDOMINAL INFECTIONS

Complicated intra-abdominal infections (cIAI) is a type of major hospital- or community-acquired infection which extend beyond the source organ into the peritoneal space and can result from perforation of or damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. cIAI is caused by different bacterial pathogens, including gram-negative aerobic bacteria, gram-positive bacteria, and anaerobic bacteria. In 2018, there were 2.9 million cIAI patients in China alone, with increasing rates of infections caused by drug-resistant bacteria, which limits the effectiveness of currently available antibiotics.

## INFORMATION ABOUT XERAVA™ (ERAVACYCLINE)

Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad *in vitro* activity against gram-negative and gram-positive pathogens that have acquired multidrug resistance and are prevalent in China. Xerava™ is currently approved for the treatment of cIAI in the US, EU, UK and Singapore and the medicine is currently under review for the treatment of cIAI in China. The Company is also developing Xerava™ for the treatment of community-acquired bacterial pneumonia. Xerava™ was licensed from Tetrphase Pharmaceuticals Inc., now a wholly owned subsidiary of La Jolla Pharmaceutical Company.

**Cautionary statement:** We cannot guarantee that we will be able to develop, or ultimately market, Xerava™ (eravacycline) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Everest Medicines Limited**  
**Wei Fu**  
*Chairman and Executive Director*

Hong Kong, 29 September 2021

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*